Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) will participate in two healthcare conferences in February 2026 with senior management presentations and webcasts available.
On Feb 12, 2026 at 2:30 PM EST CEO Dr. Neal Walker will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit. On Feb 26, 2026 at 8:40 AM EST President COO Hugh Davis will present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts will be available on the company website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ACRS
On the day this news was published, ACRS gained 2.02%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACRS fell 3.88% while peers showed mixed moves: IPHA -3.26%, IMMP -1.05%, SLN -1.22%, and modest gains in TLSA +0.69%, PRQR +0.63%. With no peers in the momentum scanner, today’s action appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Preclinical data update | Positive | +1.3% | ATI-2138 showed rapid, sustained hair regrowth in murine alopecia model. |
| Jan 12 | Trial initiation | Positive | +0.8% | Initiated Phase 1b proof-of-concept trial in atopic dermatitis for ATI-052. |
| Jan 06 | Clinical results | Positive | +0.0% | Positive interim Phase 1a ATI-052 results with favorable safety and robust PD. |
| Dec 19 | Index inclusion | Positive | -2.2% | Added to Nasdaq Biotechnology Index effective close on December 19, 2025. |
| Nov 25 | Conference participation | Neutral | -0.7% | Announced participation in Piper Sandler healthcare conference with webcast access. |
Recent fundamentally positive R&D and index-inclusion news has produced modest and sometimes mixed 1-day price reactions.
Over the last few months, Aclaris reported several R&D updates and index-related milestones. On Nov 25, 2025, participation in a healthcare conference saw a small negative reaction. Index inclusion in the Nasdaq Biotechnology Index on Dec 19, 2025 was followed by a -2.23% move. In early 2026, positive clinical and preclinical updates for ATI-052 and ATI-2138 generated only modest gains, suggesting tempered expectations despite advancing programs. Today’s conference participation fits this pattern of incremental corporate visibility news.
Market Pulse Summary
This announcement outlines Aclaris’ participation in two February conferences, continuing a pattern of investor outreach through events and webcasts available for at least 30 days. In recent months, the company highlighted positive clinical and preclinical data for ATI-052 and ATI-2138 and secured inclusion in the Nasdaq Biotechnology Index. Investors may watch how management’s conference messaging frames development timelines, capital needs, and the prioritization of key programs.
AI-generated analysis. Not financial advice.
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026.
- On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.
- On Thursday February 26, 2026, at 8:40 AM EST, Aclaris’ President and Chief Operating Officer Hugh Davis, Ph.D. will provide a corporate presentation during the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference.
A live and archived webcast of both events will be accessible on the Events page of https://www.aclaristx.com/. The webcasts will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
When will Aclaris Therapeutics (ACRS) present at the Guggenheim Emerging Outlook: Biotech Summit in 2026?
What time is Aclaris Therapeutics (ACRS) scheduled to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
Where can investors watch the Aclaris (ACRS) webcasts for the February 2026 conferences?
Who from Aclaris Therapeutics (ACRS) will appear at the February 12 and February 26, 2026 events?
Will the Aclaris (ACRS) conference presentations include clinical program updates in February 2026?
